Business Description
Ventyx Biosciences Inc
NAICS : 541713
SIC : 2833
662 Encinitas Boulevard, Suite 250, Encinitas, CA, USA, 92024
Description
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 193.13 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.49 | |||||
| 9-Day RSI | 76.55 | |||||
| 14-Day RSI | 68.52 | |||||
| 6-1 Month Momentum % | 30.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.47 | |||||
| Quick Ratio | 14.47 | |||||
| Cash Ratio | 14.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -73.45 | |||||
| ROA % | -33.41 | |||||
| ROIC % | -485.98 | |||||
| ROC (Joel Greenblatt) % | -12914.26 | |||||
| ROCE % | -35.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.57 | |||||
| Price-to-Tangible-Book | 3.57 | |||||
| EV-to-EBIT | -9.81 | |||||
| EV-to-Forward-EBIT | -7.62 | |||||
| EV-to-EBITDA | -9.83 | |||||
| EV-to-Forward-EBITDA | -7.57 | |||||
| EV-to-FCF | -13.96 | |||||
| Price-to-Net-Current-Asset-Value | 3.89 | |||||
| Price-to-Net-Cash | 3.94 | |||||
| Earnings Yield (Greenblatt) % | -10.19 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:VTYX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.809 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 68.52 | ||
| 14-Day ATR ($) | 1.240357 | ||
| 20-Day SMA ($) | 15.4775 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 9.5 - 26 | ||
| Shares Outstanding (Mil) | 50.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ventyx Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||